CLINICAL STUDY
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials
Donald E. Cutlip, MD, FACC* ,*,
Manish S. Chauhan, MD*,
Donald S. Baim, MD, FACC* ,
Kalon K. L. Ho, MD, MSc, FACC*,
Jeffrey J. Popma, MD, FACC,
Joseph P. Carrozza, MD, FACC,
David J. Cohen, MD, MSc, FACC* and
Richard E. Kuntz, MD, MSc, FACC*
* Harvard Clinical Research Institute, Boston, Massachusetts, USA
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Brigham and Women’s Hospital, Boston, Massachusetts, USA
Manuscript received January 11, 2002;
revised manuscript received April 23, 2002,
accepted May 7, 2002.
* Reprint requests and correspondence: Dr. Donald E. Cutlip, Harvard Clinical Research Institute, 900 Commonwealth Avenue, Boston, Massachusetts 02215, USA.
dcutlip{at}hcri.harvard.edu
OBJECTIVES: We sought to evaluate clinical restenosis in a large population of patients who had undergone coronary stent placement.
BACKGROUND: One-year success after coronary stenting is limited mainly by restenosis of and requirement for repeat revascularization of the treated lesion.
METHODS: We studied 6,186 patients (6,219 lesions) pooled from several recently completed coronary stent trials. Clinical restenosis was defined using three different definitions: target lesion revascularization (TLR) beyond 30 days, target vessel revascularization (TVR) beyond 30 days, and target vessel failure (TVF), defined as TVR, any death, or myocardial infarction (MI) of the target vessel territory after hospital discharge.
RESULTS: By one year, 638 (12.2%) patients had TLR, 748 (14.3%) had TVR, and 848 (16.0%) had TVF, more than two-thirds higher than the rate of these end points at six months. The severity of angiographic restenosis ( 50% follow-up diameter stenosis [DS]) in 419 of 1,437 (29%) patients undergoing routine angiographic follow-up correlated directly with the likelihood of TLR (73% vs. 26% for >70% DS compared with <60% DS). Smaller pretreatment minimum lumen diameter (MLD), smaller final MLD, longer stent length, diabetes mellitus, unstable angina, and hypertension were independent predictors of TLR. Prior MI and current smoking were negative predictors.
CONCLUSIONS: At one year after stenting, most clinical restenosis reflected TLR, which was predicted by the same variables previously associated with an increased risk of angiographic restenosis. The lower absolute rate of clinical restenosis relative to angiographic restenosis was due to infrequent TLR in lesions with less severe (<60% DS) angiographic renarrowing.
|
Abbreviations and Acronyms
| | BENESTENT | | Belgian Netherlands Stent study | | CEC | | Clinical Events Committee | | DS | | diameter stenosis | | MI | | myocardial infarction | | TLR | | target lesion revascularization | | TVR | | target vessel revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
V. Novack, D. Cutlip, N. Kleiman, M. Pencina, L. Mauri, C.-H. Yen, P. Berger, S. Goldberg, M. Kellett, R. Waksman, et al.
In-Hospital and 1-Year Outcomes Among Unselected Percutaneous Coronary Intervention Patients Treated With Either Sirolimus- or Paclitaxel-Eluting Stents: Results From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry
J. Am. Coll. Cardiol. Intv.,
August 1, 2009;
2(8):
767 - 775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C.Y. To, G. Armstrong, I. Zeng, and M. W.I. Webster
Noncardiac Surgery and Bleeding After Percutaneous Coronary Intervention
Circ Cardiovasc Interv,
June 1, 2009;
2(3):
213 - 221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ryan, W. Linde-Zwirble, L. Engelhart, L. Cooper, and D. J. Cohen
Temporal Changes in Coronary Revascularization Procedures, Outcomes, and Costs in the Bare-Metal Stent and Drug-Eluting Stent Eras: Results From the US Medicare Program
Circulation,
February 24, 2009;
119(7):
952 - 961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. Baker, A. Groothuis, M. Jonas, D. S. Ettenson, T. Shazly, E. Zcharia, I. Vlodavsky, P. Seifert, and E. R. Edelman
Heparanase Alters Arterial Structure, Mechanics, and Repair Following Endovascular Stenting in Mice
Circ. Res.,
February 13, 2009;
104(3):
380 - 387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A Ostovan, R. Mollazadeh, J. Kojuri, and M. Mirabadi
Experience with Paclitaxel-Eluting Infinnium Coronary Stents
Asian Cardiovasc Thorac Ann,
December 1, 2008;
16(6):
454 - 458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G Raja and G. D Dreyfus
Current Status of Off-pump Coronary Artery Bypass Surgery
Asian Cardiovasc Thorac Ann,
April 1, 2008;
16(2):
164 - 178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Pocock, A. J. Lansky, R. Mehran, J. J. Popma, M. P. Fahy, Y. Na, G. Dangas, J. W. Moses, T. Pucelikova, D. E. Kandzari, et al.
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.
J. Am. Coll. Cardiol.,
January 1, 2008;
51(1):
23 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Wilson and J. T. Willerson
Myocardial Revascularization with Percutaneous Devices
Card. Surg. Adult,
January 1, 2008;
3(2008):
573 - 598.
[Full Text]
|
|
|
|
|
|
|
E. Camenzind, P. G. Steg, and W. Wijns
Response to Letter Regarding Article, "Stent Thrombosis Late After Implantation of First-Generation Drug-Eluting Stents: A Cause for Concern"
Circulation,
October 16, 2007;
116(16):
e390 - e390.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Tu, J. Bowen, M. Chiu, D. T. Ko, P. C. Austin, Y. He, R. Hopkins, J.-E. Tarride, G. Blackhouse, C. Lazzam, et al.
Effectiveness and Safety of Drug-Eluting Stents in Ontario
N. Engl. J. Med.,
October 4, 2007;
357(14):
1393 - 1402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Cutlip, S. Windecker, R. Mehran, A. Boam, D. J. Cohen, G.-A. van Es, P. Gabriel Steg, M.-a. Morel, L. Mauri, P. Vranckx, et al.
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Circulation,
May 1, 2007;
115(17):
2344 - 2351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Camenzind, P. G. Steg, and W. Wijns
A Cause for Concern
Circulation,
March 20, 2007;
115(11):
1440 - 1455.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Daemen, H. M. Garcia-Garcia, N. Kukreja, F. Imani, P. P.T. de Jaegere, G. Sianos, R. T. van Domburg, and P. W. Serruys
The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus
Eur. Heart J.,
January 1, 2007;
28(1):
26 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
Circulation,
December 19, 2006;
114(25):
2850 - 2870.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ben-Gal, Y. Moshkovitz, N. Nesher, G. Uretzky, R. Braunstein, A. Hendler, E. Zivi, I. Herz, and R. Mohr
Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Patients with Diabetes Mellitus
Ann. Thorac. Surg.,
November 1, 2006;
82(5):
1692 - 1697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ryan and D. J. Cohen
Are Drug-Eluting Stents Cost-Effective?: It Depends on Whom You Ask
Circulation,
October 17, 2006;
114(16):
1736 - 1744.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Eisenberg
Drug-Eluting Stents: The Price Is Not Right
Circulation,
October 17, 2006;
114(16):
1745 - 1754.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Saia, G. Piovaccari, A. Manari, A. Santarelli, A. Benassi, E. Aurier, P. Sangiorgio, F. Tarantino, G. Geraci, G. Vecchi, et al.
Clinical Outcomes for Sirolimus-Eluting Stents and Polymer-Coated Paclitaxel-Eluting Stents in Daily Practice: Results From a Large Multicenter Registry
J. Am. Coll. Cardiol.,
October 3, 2006;
48(7):
1312 - 1318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bakhai, G. W. Stone, E. Mahoney, T. A. Lavelle, C. Shi, R. H. Berezin, B. J. Lahue, M. A. Clark, M. J. Lacey, M. E. Russell, et al.
Cost Effectiveness of Paclitaxel-Eluting Stents for Patients Undergoing Percutaneous Coronary Revascularization: Results From the TAXUS-IV Trial
J. Am. Coll. Cardiol.,
July 18, 2006;
48(2):
253 - 261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Pinto, G. W. Stone, S. G. Ellis, D. A. Cox, J. Hermiller, C. O'Shaughnessy, J. T. Mann, R. Mehran, Y. Na, M. Turco, et al.
Impact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting Stents: Results From the TAXUS-IV Trial
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
32 - 36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Perera, P Postema, R Rashid, S Patel, L Blows, M Marber, and S Redwood
Does a well developed collateral circulation predispose to restenosis after percutaneous coronary intervention? An intravascular ultrasound study
Heart,
June 1, 2006;
92(6):
763 - 767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kastrati, A. Dibra, J. Mehilli, S. Mayer, S. Pinieck, J. Pache, J. Dirschinger, and A. Schomig
Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents
Circulation,
May 16, 2006;
113(19):
2293 - 2300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Srivastava, K. V. Ramana, R. Tammali, S. K. Srivastava, and A. Bhatnagar
Contribution of aldose reductase to diabetic hyperproliferation of vascular smooth muscle cells.
Diabetes,
April 1, 2006;
55(4):
901 - 910.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Singh, B. A. Williams, B. J. Gersh, R. L. McClelland, K. K.L. Ho, J. T. Willerson, W. F. Penny, D. E. Cutlip, and D. R. Holmes Jr
Geographical Differences in the Rates of Angiographic Restenosis and Ischemia-Driven Target Vessel Revascularization After Percutaneous Coronary Interventions: Results From the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial
J. Am. Coll. Cardiol.,
January 3, 2006;
47(1):
34 - 39.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Alarcon, J. M. Arribas, V. Ruiz, L. Czupryniak, M. Pawlowski, J. Loba, R. F. Bonvini, V. Verin, R. Waksman, R. M. Wolfram, et al.
Drug-eluting coronary stents.
N. Engl. J. Med.,
December 1, 2005;
353(22):
2404 - 2408.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Douglas Jr, D. R. Holmes Jr, D. J. Kereiakes, C. L. Grines, E. Block, Z. M.B. Ghazzal, D. C. Morris, H. Liberman, K. Parker, C. Jurkovitz, et al.
Coronary Stent Restenosis in Patients Treated With Cilostazol
Circulation,
November 1, 2005;
112(18):
2826 - 2832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jonas, E. R. Edelman, A. Groothuis, A. B. Baker, P. Seifert, and C. Rogers
Vascular Neointimal Formation and Signaling Pathway Activation in Response to Stent Injury in Insulin-Resistant and Diabetic Animals
Circ. Res.,
September 30, 2005;
97(7):
725 - 733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Monraats, J. S. Rana, M. C. Nierman, N. M.M. Pires, A. H. Zwinderman, J. J.P. Kastelein, J. A. Kuivenhoven, M. P.M. de Maat, S. Z.H. Rittersma, A. Schepers, et al.
Lipoprotein Lipase Gene Polymorphisms and the Risk of Target Vessel Revascularization After Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
September 20, 2005;
46(6):
1093 - 1100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, S. G. Ellis, L. Cannon, J. T. Mann, J. D. Greenberg, D. Spriggs, C. D. O'Shaughnessy, S. DeMaio, P. Hall, J. J. Popma, et al.
Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease: A Randomized Controlled Trial
JAMA,
September 14, 2005;
294(10):
1215 - 1223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mauri, E. J. Orav, and R. E. Kuntz
Late Loss in Lumen Diameter and Binary Restenosis for Drug-Eluting Stent Comparison
Circulation,
June 28, 2005;
111(25):
3435 - 3442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jeremias, D. S. Baim, R. E. Kuntz, and D. E. Cutlip
Reply
J. Am. Coll. Cardiol.,
June 7, 2005;
45(11):
1908 - 1909.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Costa and D. I. Simon
Molecular Basis of Restenosis and Drug-Eluting Stents
Circulation,
May 3, 2005;
111(17):
2257 - 2273.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Hermiller, A. Raizner, L. Cannon, P. A. Gurbel, M. A. Kutcher, S. C. Wong, M. E. Russell, S. G. Ellis, R. Mehran, G. W. Stone, et al.
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial
J. Am. Coll. Cardiol.,
April 19, 2005;
45(8):
1172 - 1179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Ellis, J. J. Popma, J. M. Lasala, J. J. Koglin, D. A. Cox, J. Hermiller, C. O'Shaughnessy, J. T. Mann, M. Turco, R. Caputo, et al.
Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: Analysis from the TAXUS-IV trial
J. Am. Coll. Cardiol.,
April 19, 2005;
45(8):
1193 - 1200.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes, R. E. Kuntz, L. Mauri, and M. W. Krucoff
Surrogates, substudies, and real clinical end points in trials of drug-eluting stents
J. Am. Coll. Cardiol.,
April 19, 2005;
45(8):
1206 - 1212.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Rana, P. S. Monraats, A. H. Zwinderman, M. P.M. de Maat, J. J.P. Kastelein, P. A.F. Doevendans, R. J. de Winter, R. A. Tio, R. R. Frants, A. van der Laarse, et al.
Metabolic Syndrome and Risk of Restenosis in Patients Undergoing Percutaneous Coronary Intervention
Diabetes Care,
April 1, 2005;
28(4):
873 - 877.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Finn, I. F. Palacios, A. Kastrati, and H. K. Gold
Drug-eluting stents for diabetes mellitus: A rush to judgment?
J. Am. Coll. Cardiol.,
February 15, 2005;
45(4):
479 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Shrive, B. J. Manns, P. D. Galbraith, M. L. Knudtson, W. A. Ghali, and for The APPROACH Investigators
Economic evaluation of sirolimus-eluting stents
Can. Med. Assoc. J.,
February 1, 2005;
172(3):
345 - 351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mauri, E. J. Orav, A. J. O'Malley, J. W. Moses, M. B. Leon, D. R. Holmes Jr, P. S. Teirstein, J. Schofer, G. Breithardt, D. E. Cutlip, et al.
Relationship of Late Loss in Lumen Diameter to Coronary Restenosis in Sirolimus-Eluting Stents
Circulation,
January 25, 2005;
111(3):
321 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Singh, B. J. Gersh, R. L. McClelland, K. K.L. Ho, J. T. Willerson, W. F. Penny, and D. R. Holmes Jr
Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial
J. Am. Coll. Cardiol.,
January 18, 2005;
45(2):
198 - 203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Popma, M. B. Leon, J. W. Moses, D. R. Holmes Jr, N. Cox, M. Fitzpatrick, J. Douglas, C. Lambert, M. Mooney, S. Yakubov, et al.
Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Native Coronary Arteries
Circulation,
December 21, 2004;
110(25):
3773 - 3780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Finn, H. K. Gold, G. W. Stone, S. G. Ellis, D. A. Cox, J. Hermiller, C. O'Shaughnessy, J. T. Mann, M. Turco, R. Caputo, et al.
One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent in Patients With Diabetes Mellitus * Response
Circulation,
September 21, 2004;
110(12):
e318 - e319.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Cutlip, A. G. Chhabra, D. S. Baim, M. S. Chauhan, S. Marulkar, J. Massaro, A. Bakhai, D. J. Cohen, R. E. Kuntz, and K. K.L. Ho
Beyond Restenosis: Five-Year Clinical Outcomes From Second-Generation Coronary Stent Trials
Circulation,
September 7, 2004;
110(10):
1226 - 1230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Iakovou, L. Ge, I. Michev, G. M. Sangiorgi, M. Montorfano, F. Airoldi, A. Chieffo, G. Stankovic, G. Vitrella, M. Carlino, et al.
Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions
J. Am. Coll. Cardiol.,
September 1, 2004;
44(5):
967 - 971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Cohen, A. Bakhai, C. Shi, L. Githiora, T. Lavelle, R. H. Berezin, M. B. Leon, J. W. Moses, J. P. Carrozza Jr, J. P. Zidar, et al.
Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial
Circulation,
August 3, 2004;
110(5):
508 - 514.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R.P Agema, P. S Monraats, A. H Zwinderman, R. J de Winter, R. A Tio, P. A.F.M Doevendans, J. Waltenberger, M. P.M de Maat, R. R Frants, D. E Atsma, et al.
Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era
Eur. Heart J.,
July 1, 2004;
25(13):
1163 - 1170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Singh, B. J. Gersh, R. L. McClelland, K. K.L. Ho, J. T. Willerson, W. F. Penny, and D. R. Holmes Jr
Clinical and Angiographic Predictors of Restenosis After Percutaneous Coronary Intervention: Insights From the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) Trial
Circulation,
June 8, 2004;
109(22):
2727 - 2731.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Colombo and I. Iakovou
Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation
Eur. Heart J.,
June 1, 2004;
25(11):
895 - 897.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Powell, C. S. Rihal, M. R. Bell, K. J. Zehr, and D. R. Holmes Jr
Anticipated Impact of Drug-Eluting Stents on Referral Patterns for Coronary Artery Bypass Graft Surgery: A Population-Based Angiographic Analysis
Mayo Clin. Proc.,
June 1, 2004;
79(6):
769 - 772.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, S. G. Ellis, D. A. Cox, J. Hermiller, C. O'Shaughnessy, J. T. Mann, M. Turco, R. Caputo, P. Bergin, J. Greenberg, et al.
One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial
Circulation,
April 27, 2004;
109(16):
1942 - 1947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Greenberg, A. Bakhai, and D. J. Cohen
Can we afford to eliminate restenosis?: Can we afford not to?
J. Am. Coll. Cardiol.,
February 18, 2004;
43(4):
513 - 518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr, M. B. Leon, J. W. Moses, J. J. Popma, D. Cutlip, P. J. Fitzgerald, C. Brown, T. Fischell, S. C. Wong, M. Midei, et al.
Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis
Circulation,
February 10, 2004;
109(5):
634 - 640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Mack, D. J. Drenth, F. Zijlstra, P. W. Boonstra, J. W. Moses, and M. B. Leon
Sirolimus-Eluting Coronary Stents
N. Engl. J. Med.,
January 22, 2004;
350(4):
413 - 414.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kornowski and S. Fuchs
Optimization of glycemic control and restenosis prevention in diabetic patients undergoing percutaneous coronary interventions
J. Am. Coll. Cardiol.,
January 7, 2004;
43(1):
15 - 17.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr
Risk Stratification and Interventional Cardiology: Robert L. Frye Lecture
Mayo Clin. Proc.,
December 1, 2003;
78(12):
1507 - 1518.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. J. Pearce and J. F. McKinsey
Current Status of Intravascular Stents as Delivery Devices to Prevent Restenosis
Vascular and Endovascular Surgery,
July 1, 2003;
37(4):
231 - 237.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. A. Garcia and J. P. Carrozza Jr
Stenting chroniccoronary artery occlusions: One step closer?
J. Am. Coll. Cardiol.,
May 7, 2003;
41(9):
1493 - 1495.
[Full Text]
[PDF]
|
|
|
|
